Company intelligence / Profile preview
Addex Therapeutics Ltd
Geneva, Switzerlandaddextherapeutics.com ↗
- Ownership
- Public · ADXN
- Employees
- ~23
- Development stage
- Phase 2
01
Overview
Lead candidate dipraglurant (mGlu5 NAM) is being evaluated for brain injury recovery. Partner Indivior has selected a GABAB PAM for substance use disorders. Company is advancing an independent GABAB PAM program for chronic cough.
- Therapeutic areas
- PulmonologyPsychiatryNeurologyUrology
- Modalities
- Small molecule allosteric modulators
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Indivior PLCPerceptive AdvisorsJanssen Pharmaceuticals
04
Financials
- Market cap
- $3.6M
- Total revenue
- $36.6K
- Enterprise value
- $2.7M
Beyond the preview
Go deeper on Addex Therapeutics Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Addex Therapeutics Ltd.